Pre-Conference Workshop - The Intersection of Urogynecology, Sexual Health, and Hormone Therapy-Hypoactive Sexual Desire Disorder by C.Vaccaro

Hypoactive Sexual Desire Disorder by C.Vaccaro

Pdf Summary

The presentation by Dr. Christine Vaccaro discusses Hypoactive Sexual Desire Disorder (HSDD), particularly in midlife women. The agenda covers how pelvic floor disorders such as pelvic organ prolapse and urinary incontinence can negatively affect sexual desire, along with a review of the International Society for the Study of Women's Sexual Health (ISSWSH) Consensus Panel's perspective on HSDD. It also examines the roles of both FDA-approved and non-FDA-approved medications in treating this condition.<br /><br />HSDD is characterized by a persistent lack of sexual motivation lasting at least six months, manifesting through reduced spontaneous or responsive sexual desire and avoidance of situations leading to sexual activity. This lack of desire is accompanied by clinically significant distress.<br /><br />The presentation notes that HSDD prevalence is higher among partnered, sexually inactive, more educated women and those on psychotropic medications. The report emphasizes the connection between HSDD and various medical conditions, including pelvic floor disorders, malignancy, diabetes, and medication side effects like SSRIs.<br /><br />Two FDA-approved treatments are highlighted: Flibanserin, a daily oral medication that acts as a dopamine antagonist, and Bremelanotide, an on-demand injection to boost libido through dopamine pathway modulation. Both medications have demonstrated improvements in sexual desire and satisfaction, though they come with potential side effects like drowsiness and nausea.<br /><br />The presentation suggests Flibanserin has a favorable safety profile and should be taken at night to assist in sleep, with care advised when consuming alcohol or CYP34A inhibitors. Bremelanotide can induce nausea, leading to high drop-out rates in studies.<br /><br />Overall, Dr. Vaccaro's presentation urges healthcare providers to understand the multifaceted nature of HSDD, emphasizes the importance of proper diagnosis, treatment (including hormonal therapies in menopausal women), and provides educational resources for further learning.

Keywords

Hypoactive Sexual Desire Disorder

HSDD

midlife women

pelvic floor disorders

ISSWSH Consensus Panel

Flibanserin

Bremelanotide

sexual desire

FDA-approved treatments

psychotropic medications